We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Aortech International Plc | LSE:AOR | London | Ordinary Share | GB0033360586 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 126.50 | 123.00 | 130.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
27/10/2019 17:49 | Aortech relaunched itself with the equity issue at 30p last year, they have been quietly laying the foundations for a scalable medical device business utilizing an expert board and world class partners. The news flow over the next year should be fascinating and a £50m market cap should not be an unrealistic target. | landy90 | |
27/10/2019 17:21 | I hope some people understand that investing is much more complicated than they had initially expected. I do not feel sorry for those who sold too soon. They are now hoping the share price falls so they can get in cheaper. TMK | tees maar khan | |
27/10/2019 17:04 | wow 78p bones I last looked in and it was around 46p offer, I hope you put your msys losses here and got your money back. | dave4545 | |
27/10/2019 16:57 | Biomerics LLC, which has recently and usefully tweeted about its pride in being a partner of Aortech, is Aortech’s licensed manufacturer of its specialist polymers, Elasteon and ECSil. Biomerics is based in Utah, USA, where their multi-million dollar new HQ was constructed. That building has just been recognised for architectural quality: From Aortech’s perspective, potential future bigger scale partners and distributors should be very comforted by the investment that Biomerics has made in its own infrastructure and, by extension, that of Aortech’s. | bones | |
27/10/2019 14:54 | The lack of noise on Twitter is being addressed | the stigologist | |
26/10/2019 22:33 | Been in this since mid-June last year. Have been mostly reading other people's input and not really felt the need to comment. This company is undervalued by a country mile and looks like the traders are exhausted, sad and bored? Plenty of cautionary tales on AIM in these tough markets. It's hard to resist the urge to post, especially after seeing the share price fly over the past couple of trading sessions. There is no noise surrounding AorTech on Twitter which can only be a good thing. Onwards and upwards! TMK | tees maar khan | |
26/10/2019 13:53 | Stay long..I am. | blueball | |
26/10/2019 12:41 | I've also stuck with it despite having seen its decline from July 2018 onwards. The fundamentals are right, but as you say markets are funny things. | ivor hunch | |
26/10/2019 06:47 | I'm still here tooAmazed (but genuinely pleased) that the market hasn't noticed this one, cos if it did the board would be full of quick buck merchants and we could do without those.....imo | herschel k | |
25/10/2019 21:37 | Good chart. Looks like a break out of 52 week highs on Closing basis. Re Fundamentals now the Overhang has gone we should be looking at the historic invested capital of c.60m as a starting point for any serious revaluation here so around the Broker's 400p target really. | the stigologist | |
25/10/2019 17:40 | Yes, and arguably the breakout has a long way to run to really BREAK OUT! Given what the company has achieved in less than 2 years and should command way more value now than in mid 2018, this breakout should be just starting. Markets are strange animals though! free stock charts from uk.advfn.com | bones | |
25/10/2019 17:21 | Idiot. [Double post] | the stigologist | |
25/10/2019 17:21 | Finished just below 52 week high of 78.50 but its breaking out anyway so only a matter of time at this rate. | the stigologist | |
25/10/2019 16:08 | I reckon that last trade was a buy rather than as shows in red? | coolhandfluke | |
25/10/2019 13:54 | Amen to that, langland. | bones | |
25/10/2019 13:07 | My earlier post was a little bit tongue in cheek but well done everyone for taking the trouble to respond. So far this month aor is up about 70% and no one has noticed -it seems. And we are still not much more than a 10mn mkt. cap. This seems plainly ridiculous when one of my old favourites AGL has a 135mn mkt. cap. and is still loss making and has to be supported by placings every so often. The potential here may not be as big as AGL but I certainly think there is scope for us to become 50-100mn within the next 2 years. Like another poster here I was intrigued that Biomerics tweeted last week. After about 5 years of being associated with aor why tweet now? | langland | |
25/10/2019 10:47 | langland: I'm still here and appreciating the comments on the board. The points I would have made following the trading update were made by others although I also appreciate Aor's prudent cash management. Interesting that Aor have tied their potential success of polymer valves to one of their competitors: AorTech has noted the progress made by certain former employees in achieving "first in man" with a polymer valve. We view this development positively, as a regulatory pathway has now been established for polymeric valves and testing protocols agreed. This provides us with confidence that our valve will have similar success, especially as a result of the recent improvements in design referred to above. Look forward to the update in a month from now. | cfb2 | |
25/10/2019 10:25 | Absolutely, Net, and if the polymeric valve becomes the de facto standard (as it surely will on cost grounds alone as well as its multi-faceted advantages over current technologies), the market extends not only to the ever-expanding older populations in developed nations but also to hitherto deprived regions of poorer populations where there is a desperate need in younger people (AOR has already cited India where many children develop diseases that lead to heart valve failures before the 30th birthday of many of the afflicted). The expense and need for ongoing medication means that current remedies are out of reach of vast numbers of people. Robotically produced polymeric valves will be vastly cheaper to produce than hand-stitched animal tissue models of today and should require far less medical maintenance in the way of drugs and hospital visits. The only question then will be... are there enough qualified surgeons?! | bones | |
25/10/2019 10:14 | I'm still here, but dont know much about hearts. I do know hearts wear out a great deal as we age. So the market is massive as Baby Boomers the world over are retiring in ever larger numbers every year and lots of them have lots of money. | netcurtains | |
25/10/2019 10:02 | Ha! Long may it stay that way until the share price is at least a few quid. | bones | |
25/10/2019 09:35 | Yes, bones, I thought I should put that vital piece of information on here since I figured it must be my turn to post something since there are only about half a dozen or so of us left here! | langland | |
25/10/2019 09:17 | I see the seller today of 5,143 shares at 73.5 is likely to be the same person that bought 5,143 yesterday at 75. Discuss. Edit: crossed with your post Langland! | bones |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions